東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Chemical genomics in yeast: Linking ...

Parsons, Ainslie Bennett.

FindBook

Google Book

Amazon

博客來

Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets./
作者:	Parsons, Ainslie Bennett.
面頁冊數:	148 p.
附註:	Source: Dissertation Abstracts International, Volume: 67-07, Section: B, page: 3569.
Contained By:	Dissertation Abstracts International67-07B.
標題:	Biology, Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR16019
ISBN:	9780494160190

Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets.
Parsons, Ainslie Bennett.

Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets. - 148 p.

Source: Dissertation Abstracts International, Volume: 67-07, Section: B, page: 3569.

Thesis (Ph.D.)--University of Toronto (Canada), 2006.

Target specific chemical inhibitors are highly valuable as both research tools and therapeutic leads, but it is often difficult to identify their mechanism of action or cellular target. Here I have studied genome-wide chemical-genetic interaction profiles in the budding yeast Saccharomyces cerevisiae , by testing the complete set of viable deletion mutants for hypersensitivity to inhibitory compounds. Integration of chemical-genetic and genetic interaction data reveals information about the mode of action of bioactive compounds. First, in a series of proof-of-concept experiments I showed that because a loss-of-function mutation in a gene encoding the target of an inhibitory compound models the primary effect of the compound, crossing such a mutation into the set of viable mutants and scoring the resultant double mutants for reduced fitness generates a genetic interaction profile for the target gene resembling the chemical-genetic interaction profile of its inhibitory compound. Therefore, clustering the compound-specific profiles with a compendium of large-scale genetic interaction profiles enables the identification of target pathways or proteins and thus provides a powerful means for inferring mechanism of action. In the second phase of this project, I expanded our matrix of chemical-genetic interactions by profiling 85 diverse compounds and natural product extracts, including a number of human therapeutics, using parallel fitness tests and a microarray-based readout. Hierarchical clustering of the dataset associates compounds of similar mode of action and reveals insight into the cellular pathways affected by the compounds. In particular, my analysis establishes a cell membrane target for papuamide B, a high molecular weight cyclic lipopeptide with potent anti-fungal and anti-HIV activity.

ISBN: 9780494160190Subjects--Topical Terms:

1017730
Biology, Genetics.

Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets.
LDR:02633nmm 2200241 4500 001 1834160
005 20071119110201.5
008 130610s2006 eng d
020 $a 9780494160190
035 $a (UMI)AAINR16019
035 $a AAINR16019
040 $a UMI $c UMI
100 1 $a Parsons, Ainslie Bennett. $3 1922826
245 1 0 $a Chemical genomics in yeast: Linking biologically active compounds to their intracellular targets.
300 $a 148 p.
500 $a Source: Dissertation Abstracts International, Volume: 67-07, Section: B, page: 3569.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2006.
520 $a Target specific chemical inhibitors are highly valuable as both research tools and therapeutic leads, but it is often difficult to identify their mechanism of action or cellular target. Here I have studied genome-wide chemical-genetic interaction profiles in the budding yeast Saccharomyces cerevisiae , by testing the complete set of viable deletion mutants for hypersensitivity to inhibitory compounds. Integration of chemical-genetic and genetic interaction data reveals information about the mode of action of bioactive compounds. First, in a series of proof-of-concept experiments I showed that because a loss-of-function mutation in a gene encoding the target of an inhibitory compound models the primary effect of the compound, crossing such a mutation into the set of viable mutants and scoring the resultant double mutants for reduced fitness generates a genetic interaction profile for the target gene resembling the chemical-genetic interaction profile of its inhibitory compound. Therefore, clustering the compound-specific profiles with a compendium of large-scale genetic interaction profiles enables the identification of target pathways or proteins and thus provides a powerful means for inferring mechanism of action. In the second phase of this project, I expanded our matrix of chemical-genetic interactions by profiling 85 diverse compounds and natural product extracts, including a number of human therapeutics, using parallel fitness tests and a microarray-based readout. Hierarchical clustering of the dataset associates compounds of similar mode of action and reveals insight into the cellular pathways affected by the compounds. In particular, my analysis establishes a cell membrane target for papuamide B, a high molecular weight cyclic lipopeptide with potent anti-fungal and anti-HIV activity.
590 $a School code: 0779.
650 4 $a Biology, Genetics. $3 1017730
690 $a 0369
710 2 0 $a University of Toronto (Canada). $3 1017674
773 0 $t Dissertation Abstracts International $g 67-07B.
790 $a 0779
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR16019